



Uploaded to the VFC Website

▶▶▶ 2019 ◀◀◀

This Document has been provided to you courtesy of Veterans-For-Change!

Feel free to pass to any veteran who might be able to use this information!

For thousands more files like this and hundreds of links to useful information, and hundreds of "Frequently Asked Questions, please go to:

[Veterans-For-Change](#)

If Veterans don't help Veterans, who will?

Note:

VFC is not liable for source information in this document, it is merely provided as a courtesy to our members & subscribers.



Appendix: Questionnaire on Exposure to Asbestos

Personal Data

Name _____
 Street address _____
 Postal code and city/town _____
 Area code and home telephone
 number _____
 Occupation (current or most recent) _____
 Employer (current or most recent) _____
 Year of retirement (for pensioners) _____

Information on Sector of Employment

Record the work time (from year to year) for sectors and tasks in which you have primarily worked (e.g., years 1945–1946, 1963–1968, 1975–).

Building industry	Years
1. Installing new pipes _____	_____
2. Disassembling old pipelines _____	_____
3. Pipe insulation work _____	_____
4. Other insulating works _____	_____
5. Electrical installations works _____	_____
6. Other construction work in new buildings _____	_____
7. Other construction work in renovations _____	_____
Shipbuilding industry	Years
8. Equipment work (after launching) _____	_____
9. Works in renovated ships _____	_____
10. Asbestos spraying and insulation works _____	_____
11. Other works in the shipbuilding industry _____	_____
Asbestos product industry and mines	Years
12. Work in the manufacturing of asbestos products _____	_____
13. Work in asbestos mines _____	_____
14. Other work in the asbestos product industry _____	_____
Power plants	Years
15. Insulating and dismantling boilers _____	_____

Lining of industrial ovens (glass, cement, metal industry, foundries)	Years
16. Insulating and dismantling ovens _____	_____
Car repair shops	Years
17. Brake and clutch work _____	_____
18. Other work in car repair shop _____	_____
19. Other work-related matters _____	_____

List the sectors other than those listed above that you have primarily been employed in. Mention your occupation during these work periods.

Occupation	Years
e.g., farmer	1955–1965
_____	_____
_____	_____
_____	_____

Information on Occupation

Record the work time (from year to year) for occupations in which you have primarily worked (e.g., years 1968–1970, 1972–1974).

Construction industry occupations	Years
1. Insulation sheet metal worker _____	_____
2. Insulator _____	_____
3. Cleaner _____	_____
4. Tin worker, sheet metal worker _____	_____
	Years
5. Driller _____	_____
6. Pipe fitter _____	_____
7. Pipe insulator _____	_____
8. Construction worker _____	_____

	Years
9. Female construction worker_____	_____
10. (Construction site) cleaner_____	_____
11. Renovation worker (janitor)_____	_____
12. General worker, unskilled man_____	_____
13. Electricity installer, electrician_____	_____
14. Filler applier_____	_____
15. Other occupations in the building industry _____	_____
Please specify: _____	_____

Shipbuilding industry occupations	Years
16. Insulator_____	_____
17. Maintenance technician_____	_____
18. Ship cleaner_____	_____
19. Plater_____	_____
20. Firefighter_____	_____
21. Pipe fitter_____	_____
22. Interior decoration fitter_____	_____
23. Electricity installer, electrician _____	_____
24. Other shipbuilding occupations _____	_____
With work taking place in a ship in the outfitting stage _____	_____
Please specify: _____	_____

Asbestos product industry occupations	Years
25. Asbestos sewer_____	_____
26. Asbestos miller_____	_____
27. Asbestos sawyer_____	_____
28. Asbestos pipe maker_____	_____
29. Insulation mass mixer_____	_____
30. Quarry employee_____	_____
31. Beater worker _____	_____
32. Maintenance technician_____	_____
33. Machine operator, machine user_____	_____
34. Quarry employee_____	_____
35. Cleaner (production) _____	_____
36. Bagger_____	_____
37. Other asbestos industry occupations _____	_____
Please specify: _____	_____

Power plant occupations	Years
38. Industry_____	_____
39. Oven operator_____	_____
40. Melter_____	_____

Asbestos Exposure

Have you been involved in the following tasks with a possibility of exposure to asbestos-containing products? Answer by ticking the box next to the applicable option.

If your answer is "yes," please enter the years when you were employed in such work (e.g., 1956–1966, 1968–1982)

	No	Don't know	Yes	Years
1. Dismantling asbestos-containing materials				_____
2. Carrying out asbestos spray application tasks (fire protection, heat and acoustic insulation)				_____
3. Carrying out pipe insulation tasks using insulation mass				_____
4. Fitting boiler, oven, hot water boiler, machinery and electric equipment, heat and fire insulation				_____
5. Fitting asbestos cement plates, asphalt felt on roofs				_____
6. Fitting wall panels, interior wall panels, interior lining panels, acoustic panels, and fire protection panels				_____
(examples of commercial products can be listed here)				_____
7. Dismantling vinyl flooring or mass flooring				_____

Index

A

ABPs. *See* Aminobiphenyls (ABPs)

Actinic keratosis (AK), 380–381

Adenocarcinomas

- intestinal-type adenocarcinomas (ITACs), 155–157
- non-intestinal type of adenocarcinomas (non-ITACs), 155–157
- small intestine, 127
- sinonasal cancers, 154–155

AES. *See* Auger electron spectroscopy (AES)

Agricultural Health Study (AHS)

- atrazine/cyanazine, 505
- organochlorine pesticide exposure, 506
- phenoxy herbicides, 504

AHS. *See* Agricultural Health Study (AHS)

AK. *See* Actinic keratosis (AK)

Aluminum production, 465, 467

Aminobiphenyls (ABPs), 476

Animal exposures

- farm animals, 508
- livestock industry, 507
- proportionate mortality, 508
- serological tests, 508
- zoonotic viruses, 507

AP endonuclease 1 (APEX1), 234

APEX1. *See* AP endonuclease 1 (APEX1)

Apoptosis

- and angiogenesis, 40
- and cell proliferation, 217
- EGFR-dependent pathway, 213
- inflammatory process, 213

Aromatic amines

- benzidine, 461
- b-naphthylamine, 461, 464
- dye industry, 461
- IARC, 465
- N-oxidation, 465
- rubber industry, 464–465

Arsenic

- chronic exposure, 384
- cocarcinogen, 220
- dimethylation, 42
- DNA ligase activity, 220
- epidemiological evidence, 220
- epigenetic mechanisms, 220
- exposure and lung cancer, 189
- kidney cancer, 450–451
- lung cancer, 189
- metal-induced lung carcinogenesis, 219–220
- MMA and DMA, 220
- and nickel, 12
- signal transduction pathways, 220

and silica, 200

skin carcinogen, 384

Asbestos

- and allelic imbalance, 246
- apoptosis, 213–214
- attribution, 249
- cessation, exposure, 257
- chromosomal region, 246
- clastogenicity, 214–215
- CNA and gene expression screening, 245
- colorectal cancer risk, 129
- community-based studies, 258–259
- dose-response and frequency, 246–247
- dose-response relationship, 259
- epigenetic effects, 215
- epigenetic markers, 248–249
- exposure, 11–12
- fibers, effect, 260
- frequent methylation, 246
- gene expression markers, 248
- industry-based studies
 - cohort studies, mesothelioma, 253–255
 - scatter plot, ratio, 256
 - SMR, pleural neoplasms, 256
- kidney cancer, 452–453
- laryngeal cancer, 170–174
- liver angiosarcoma, 567
- lung cancer
 - asbestosis, 190, 192
 - assessment, 192–194
 - epidemiological and pathologic study, 189–190
 - hypotheses, 190
- malignant transformation, 211
- MAPK/ERK pathway, 214
- mesothelioma, risk, 253
- MMs (*see* Malignant mesotheliomas (MMs))
- occupational carcinogens, 5
- organs, risk, 259
- oxidative stress and inflammation, 212–213
- peritoneal mesothelioma, risk, 259
- pleural plaques, risk, 259
- polyploidy, 248
- respiratory cancer risk, 2
- synergistic mechanisms and tobacco smoke, 215
- toxicity and carcinogenicity, 212
- tumor suppressor gene and oncogene markers, 248
- types, 245

Ataxia-telangiectasia-mutated (ATM), 234

ATM. *See* Ataxia-telangiectasia-mutated (ATM)

Auger electron spectroscopy (AES), 204

B

- BAC. *See* Bronchioloalveolar cell carcinoma (BAC)
- Basal cell carcinoma (BCC), 380, 386
- BCC. *See* Basal cell carcinoma (BCC)
- BCME. *See* Bis(chloromethyl) ether (BCME)
- Beryllium
- epigenetic alterations, 221
 - genotoxicity and carcinogenicity, 221
 - hydroxide, 221
 - and polymorphism, 25
 - properties, 194
- The Beryllium Industry Scientific Advisory Committee (BISAC), 194
- Biomarkers
- bladder cancer, exposure assessment, 475
 - carcinogenesis, 157
 - lung cancer
 - metal-induced lung carcinogenesis, 219–223
 - oxidative DNA damage, 218–219
 - PAH exposure, 218
 - MM, chromosomal imbalances
 - array CGH studies, 326–327
 - cyclin-dependent kinase inhibitor 2A (CDKN2A)*, 327
 - karyotype analyses, 326
 - and lung adenocarcinoma, 328
 - mutations, 329
 - and putative candidate genes, 327–328
 - structure and number, 326
 - screening, occupational cancer, 574
 - serum, 579
- Biphasic malignant mesothelioma
- diagnosis, 292
 - and epithelioid (*see* Epithelioid malignant mesothelioma)
 - and sarcomatoid, 285–286
- BISAC. *See* The Beryllium Industry Scientific Advisory Committee (BISAC)
- Bis(chloromethyl) ether (BCME), 195
- Bladder cancer
- assessment
 - biomarkers, 475
 - chemical/physical agent, 475
 - JEM, 474–475
 - materials, 474
 - questionnaires, 474
 - characteristics, 578
 - clinical and pathological features, 475
 - description, 461, 476–477
 - exposures, occupations and industries evaluation
 - aromatic amines, dye and rubber industry (*see* Aromatic amines)
 - attributable risk, 473
 - blue-collar occupations, 471–472
 - coal gasification and asphalt workers, 465, 467
 - description, 461–462
 - diesel engine exhaust, 467–468
 - hairdressers and barbers (*see* Hairdressers and barbers, risk for bladder cancer)
 - industrialized countries, 473–474
 - industries, Europe, 471–472
 - leather workers, 471
 - machinists and metal workers, 471
 - PAHs and aluminum production, 465, 467
 - painters, 468–469
 - printers, 470–471
 - SIRs, chimney sweepers and hairdressers, 471–472
 - textile industry, 471
 - white-collar occupations, 472
 - in women, 473
 - genetic susceptibility
 - benzidine exposure and lifetime smoking, 476
 - familial clustering, 475–476
 - GWAS, 476
 - metabolic polymorphisms, 475
 - NAT2, 476
 - noninvasive tests, 578
 - non-occupational risk factors, 474
 - “prescreening” tests, 578
 - urine cytology, 578
- Bone tumors, 558
- Brain cancer, adults
- asthma, allergy and eczema, 485
 - glioma, 484
 - hypothesis, 485
 - N*-nitroso compounds, 485
- Breast cancer
- female, 391–401
 - inconclusive environmental exposures, 400
 - male, 401–403
 - polychlorinated biphenyls (PCBs), 400
 - primary prevention, occupational cancer, 565–567
 - registries, occupational disease, 583
- Bronchioloalveolar cell carcinoma (BAC), 181–182
- Burden of occupational cancer
- agent and human cancer, 531
 - approaches, 531–532, 537
 - asbestos and polycyclic aromatic hydrocarbons, 547–548
 - carcinogen and cancer, 532, 537
 - CAREX, 536–537
 - chronic diseases, 532–533
 - deaths and registrations, 538–540, 548
 - Delphic Principle, 532
 - description, 546–547
 - exposure-response, 532
 - Global Burden of Disease, 549
 - hairdressing, 548
 - HALYs (*see* Health-adjusted life years (HALYs))
 - healthy worker effect, 547
 - IARC, 531–536
 - industry sectors and carcinogenic agent, 540, 542
 - interventions, 548
 - laryngeal and stomach cancers, 532
 - latency, 548
 - leukemia, 547
 - Levin’s and Miettinen’s method, 537
 - lung cancer and mesothelioma, 540–541
 - lymphohematopoietic malignancies, 548
 - Monte Carlo simulations, 537
 - NMSC, 540
 - prediction
 - attributable fraction approach, 537
 - carcinogenic agents, 541
 - deaths and cancer registrations, 541
 - exposure level categories, 538
 - forecast lung cancers, 541, 544
 - industry sector/carcinogenic agent, 541–543
 - intervention, 538
 - lifetime risk approach, 537
 - RCS, 541
 - REP, 537–538
 - WEL, 541
 - REP, 536
 - risk factors and high-risk populations, 531
 - service and construction industries, 541
 - sinonasal cancer, 541
 - smoking, lung cancer, 532

- sources, bias, 547
- YPLLs, 545–546
- 1,3-Butadiene
 - carcinogenicity, 12
 - carcinogens, detoxification, 26
 - lymphohematopoietic cancers, 498
- C**
- Cadmium (Cd)
 - apoptosis resistance, 221
 - breast cancer, inconclusive environmental exposures, 400
 - carcinogenicity, 221
 - chromium, 117
 - chronic exposure, 195
 - and compounds, 12
 - epigenetic mechanisms, 221
 - human lung carcinogen, 221
 - iron and copper, 221
 - kidney cancer, 450–451
 - lung cancer, 194–195
 - occupational exposure, 194–195
 - oxidative DNA damage, 221
 - prostate cancer, 12
 - renal cortex and nephrotoxic effects, 450
 - tobacco smoking, 189
 - zinc, 29
- Cancer registries, occupational disease
 - awareness, 584
 - biobanks and pathology specimens, 588
 - cause-of-death registration, 585–586
 - challenges, 587
 - clustering, 584
 - death registers, 584
 - description, 583
 - genes, intracellular regulation and carcinogenic process, 588
 - health-care services, 583
 - industrial hygiene, 584
 - information bias, 586–587
 - insurance and compensation rules, 584
 - intervention studies and observational design, 586
 - nordic experience and cooperation
 - background data, 587–588
 - cancer incidence, 588
 - censuses, 588
 - copper smelters, 588
 - exposure and diagnosis, 588
 - PIDs and linkage, 587
 - population-based registers, 587
 - personnel lists, family registers and pension funds, 585
 - protection, personal data, 586
 - Ramazzini, breast cancer, 583
 - selection bias, 586
 - surveillance and research, 584–585
- Carcinogenesis
 - angiogenesis, 33
 - in bile ducts, 133–134
 - chemical
 - alkylation, 35
 - apurinic/aprimidinic, 35
 - bulky adducts, 35–36
 - direct carcinogens, 35
 - DNA adducts, 35
 - exogenous, 36
 - genetic and epigenetic alterations, 36
 - mutagenicity, 35
 - procarcinogens, 35
 - toxic metals or metalloids, 36
 - definition, 33
 - DNA damage, environmental and occupational sources, 34–35
 - DNA repair (*see* DNA repair)
 - endogenous mechanisms
 - hydrolysis, 36
 - lipid peroxidation, 36
 - spontaneous DNA damage, 36
 - epigenetics and cancer (*see* Epigenetics)
 - field cancerization and expanding fields, 33
 - hallmark capacities, 33
 - human biomarker studies, 157
 - ionizing radiation-induced, 223–224
 - loss of heterozygosity (LOH), 33
 - mechanisms, 157
 - metastasis, 33
 - occupational exposures, 157
 - oncogenes activation, 33
 - pathomechanisms, 157
 - physical
 - electromagnetic field (EMF) nonionizing radiation, 34
 - gamma radiation, 34
 - primary mutagenic effect, 34
 - reactive oxygen species (ROS), 34
 - ultraviolet light, 34
 - tumor suppressor genes inactivation, 33
 - wood dust (*see* Wood dust, SNC)
- Carcinogen exposure (CAREX) database, 387, 475, 536–537, 569
- Carcinogen-metabolizing genes
 - CYPs, 231–232
 - EPHX1, 232
 - GSTs, 232–233
 - MnSOD and MPO, 233
 - NATs, 233
- CAREX. *See* Carcinogen exposure (CAREX) database
- Cause-of-death registration, 585–586
- CCA. *See* Cholangiocarcinoma (CCA)
- Central nervous system (CNS)
 - acrylonitrile, 492
 - astrocytic tumors, 484
 - astrocytomas, 481
 - benign tumors, 483
 - brain cancer, 481, 482–483 (*see also* Brain cancer, adults)
 - Caucasian populations, 484
 - computer-assisted tomography and magnetic resonance imaging, 484
 - embryonal tumors, children, 481
 - ependymoma, 483
 - formaldehyde, 492
 - gangliogliomas, 481, 484
 - glial cells, 481
 - GloboCan and NordCan, 483
 - heterogeneous, 483
 - lead exposure, 492
 - meningiomas, 483
 - mercury, 492
 - neovascularization and necrosis, 481
 - neuroepithelial tumors and glioma, 482–483
 - occupational risk factors
 - exposure assessment, 485
 - industry, 485–486
 - ionizing radiation, 486–487
 - nonionizing radiation (*see* Nonionizing radiation)
 - oligodendroglioma, 484
 - organic solvents, 491

Central nervous system (CNS) (*cont.*)

- pathogenesis
 - astrocytomas, 482
 - GBM, 482–483
 - IDH1, 482
 - oligodendroglioma, 483
- pesticides, 490–491
- SEER, 483–484
- vinyl chloride, 491–492

Cervical cancer

- cohort study, 415
- etiology and lifestyle-related risk factors, 411–412
- Finnish record-linkage study report, 415–416
- mortality to incidence ratio, 409
- socioeconomic status and HPV infection, 415
- tetrachloroethylene, 414–415

Chest X-ray (CXR), 576–579

Children, occupational carcinogens and cancer

- agriculture, 562
- asbestos, 561–562
- bone tumors, 558
- causative agent, 561
- child laborers, 561
- Current Population Survey (CPS), 561
- description, 551
- exposures, 561
- germ cell tumors, 559
- health effects, 561
- hematologic and lymphoid malignancies (*see* Hematologic and lymphoid malignancies)
- National Longitudinal Survey of Youth 1997 (NLSY97), 561
- nervous system tumors (*see* Nervous system tumors, children)
- neuroblastoma, 557
- paternal occupational exposure (*see* Paternal occupational exposures)
- pediatric cancer and child labor, 562
- urinary system malignancies
 - maternal occupational exposures, 557–558
 - paternal occupational exposures, 558

Chloromethyl methyl ether (CMME), 195

Cholangiocarcinoma (CCA)

- bile ducts, carcinogenesis, 133
- extrahepatic, 130
- intrahepatic, 130
- tyrosine phosphorylation, 133–134

Choriocarcinoma, 410, 413, 419

Chromium

- airborne, 153
- DNA damage, 222
- epigenetic mechanisms, 222
- exposure, 29, 42, 149
- hexavalent, 152
- human lung carcinogens, 221
- intracellular reduction, 222
- kidney cancer, 450–451
- and nickel, 148, 451
- refractory brick and electroplating, 196

Chronic lymphocytic leukemia (CLL)

- follicular lymphoma, 515
- and IARC, 510
- miRNA expression and cancer, 44
- myeloid cell and lymphoid leukemias, 497

CLL. *See* Chronic lymphocytic leukemia (CLL)CMME. *See* Chloromethyl methyl ether (CMME)

Coal dust, 196–197

Coal gasification and asphalt workers, 465, 467

Colon cancer, 128

Computed tomography (CT)

- internal mammary chain lymphadenopathy, 268–269
- para-aortic lymphadenopathy, 268–269
- pericardial thickening, 267–268
- pericardium and mediastinal pleura, 267
- pleural effusion, 266–267
- tumor, oblique fissure, 267–268
- unusual solitary dominant mass, 267, 269

CT. *See* Computed tomography (CT)CXR. *See* Chest X-ray (CXR)CYPs. *See* Cytochrome P450s (CYPs)

Cytochrome P450s (CYPs)

- catalytic activities, 232
- “debrisoquine/sparteine” polymorphism, 231
- detoxifying reactions, 231
- ethanol-inducible enzyme, 232
- hepatic enzyme, 232
- lung carcinogenesis, 232
- xenobiotic metabolism, 26

D

Desmoplastic malignant mesothelioma

- diagnosis, 294–295
- sarcomatoid, 285

Diesel engine exhaust

- benzene, 467
- benzidine/b-naphthylamine, 473
- European case-control studies, 468
- and gasoline engine emissions, 11
- JEM, 468
- laryngeal cancer, 176
- urinary bladder, 467
- and vehicle repair mechanics, 82

Dimethylarsinic acid (DMA), 220

DNA repair

- base excision repair (BER), 37
- and cell-cycle genes
 - APEX1, 234
 - ATM, 234
 - ERCC1 and ERCC2, 234
 - XPA and XPC, 234
 - XRCC1, 235
- classes, 37
- damaging events, 36–37
- direct reversal repair, 37
- DNA damage tolerance, 39
- double-stranded DNA breaks (DSB), 38
- interstrand cross-link repair, 38
- mismatch repair, 38
- nucleotide excision repair (NER), 37
- rates, 37

EEBUS. *See* Endobronchial ultrasound (EBUS)EBV. *See* Epstein-Barr virus (EBV)EDXA. *See* Energy-dispersive x-ray analysis (EDXA)EELS. *See* Electron energy loss spectrometry (EELS)EGFR. *See* Epidermal growth factor receptor (EGFR)

Electromagnetic fields (EMF)

- carcinogenicity, 517
- hypothesis, 400
- ionizing radiation, 402
- leukemia, 518, 553

- lymphohematopoietic malignancies, 518
 - paternal occupation exposure, 556
 - radon gas, 15
 - Electron energy loss spectrometry (EELS), 204
 - ELF-MFs. *See* Extremely low-frequency magnetic fields (ELF-MFs)
 - EMA. *See* Epithelial membrane antigen (EMA)
 - EMF. *See* Electromagnetic fields (EMF)
 - Endobronchial ultrasound (EBUS), 187
 - Endometrial cancer
 - etiology and lifestyle-related risk factors, 412–413
 - incidence rate, 409
 - malignant tumors, 419
 - occupational exposures, 416
 - Energy-dispersive x-ray analysis (EDXA), 194, 204
 - Engine exhaust
 - gasoline and diesel, 515–516
 - IARC, 452
 - mouth and pharynx cancer, 82
 - ovarian cancer, 418
 - Environmental tobacco smoke (ETS), 119, 216, 244, 540
 - Epidermal growth factor receptor (EGFR)
 - abnormalities, 482
 - apoptosis, 213
 - asbestos-induced oxidative stress, 214
 - gene copy, 163
 - human MM cells, 311
 - immunohistochemistry, 163
 - in lung adenocarcinoma, 329
 - MAPK/ERK pathway, 214
 - mutation, 244
 - patients with asbestosis, 248
 - Epigenetics
 - alter gene expression, 39
 - CpG methylation and point mutations, 41
 - DNA methylation
 - cancer development, 40
 - CpG islands (CGI), 40
 - definition, 40
 - DNA methyltransferase (DNMT) activity, 41
 - environmental and occupational exposures, 40
 - hypermethylation, 40
 - hypomethylation, 40
 - inducible nitrous oxide (*iNOS*) gene, 41
 - promoter, 40
 - transcriptional silencing, 39–40
 - transposable elements (TE), 40
 - and environmental/occupational exposure
 - chromium exposure, 29
 - DNA methylation, 29
 - DNA methyltransferase (DNMT) activity, 29
 - environmental exposures, 29
 - epigenetic configuration, 28
 - genome-wide hypomethylation, 29
 - intrauterine development, 29
 - localized promoter hypermethylation, 29
 - ultraviolet radiation exposure, 29
 - exposure periods, 39
 - histone modifications
 - acetylation, 41–42
 - arsenic, 42
 - chromatin, 41
 - chromium exposure, 42
 - methylation, 42
 - nickel, 42
 - nucleosome, 41
 - microRNAs (miRNA)
 - Argonaut (Ago) protein, 44
 - chronic lymphocytic leukemia (CLL), 44
 - definition, 42
 - environmental exposures, 44
 - microprocessor, 43
 - pre-miRNAs, 43–44
 - pri-miRNA, 43
 - processing and posttranscriptional regulation, 43
 - RISC-loading complex (RLC), 44
 - TAR RNA-binding proteins (TRBP), 44
 - monozygotic twins, 39
 - Epithelial membrane antigen (EMA), 292, 336–337
 - Epithelioid malignant mesothelioma
 - and biphasic, 286
 - effusion cytology
 - chronic persistent injury, 286–287
 - mesothelial lesions, 288
 - metastatic carcinomas, 287–288
 - and metastatic pleural tumors, 288–289
 - and ovarian/peritoneal serous carcinoma, 288, 290
 - pancytokeratins, 288
 - tumor types, 288–289
 - papillary structures, 286–287
 - ultrastructural features, 286
 - Epstein-Barr virus (EBV), 152, 154, 161
 - ETS. *See* Environmental tobacco smoke (ETS)
 - Excision repair cross-complimentary groups 1 (ERCC1), 234, 322
 - Excision repair cross-complimentary groups 2 (ERCC2), 121, 234
 - Extrahepatic biliary tract cancer
 - extrahepatic biliary ducts, 135
 - gallstones, 135
 - occupational risk factors, 135
 - Extremely-low-frequency electric and magnetic fields (ELF-EMFs)
 - female breast cancer, 399–400
 - male breast cancer, 402
 - Extremely low-frequency magnetic fields (ELF-MFs), 553–555, 557, 560
- ## F
- Fallopian tube cancers, 410, 413, 419
 - Farming and pesticides
 - AHS, 499, 503–504
 - heterogeneity, 498
 - lymphoid cell neoplasms, 499
 - meta-analyses, 498–499
 - myeloid leukemia, 498–499
 - non-Hodgkin lymphoma, case-control studies, 499–502
 - prostate cancer
 - Agricultural Health Study cohort, 426–427
 - butylate and cumaphos, 427
 - chlorinated insecticides, 427
 - dose-response relationship, 427
 - heterogeneity, 426
 - hormonal effects, 428
 - meta-analyses and systematic reviews, 425–426
 - methyl bromide and dichlorvos, 427–428
 - organophosphate insecticides, 427
 - PCBs, 428
 - plasma/adipose tissue levels, 428
 - thiocarbamate herbicide butylate, 427
 - types, 425
 - wide and heterogeneous, 425

Farming and pesticides (*cont.*)

- testicular cancer
 - childhood and early adulthood, 431–432
 - endocrine disrupting agents, 431
 - fertilizer, 431
 - incidence, 430
 - job-exposure matrix, 431
 - meta-analysis, 430–431
 - organochlorine, 431
 - phenols and therein, 431

Female breast cancer

- epidemiology
 - description, 391
 - and lifestyle-related risk factors, 391–394
 - world age-standardized incidence and mortality rates, 391–392
- estimated proportions, 401
- gene-environment studies, 401
- lifestyle-related risk factors
 - alcoholic beverages, 393–394
 - diet, body size and physical activity, 392–393
 - exogenous hormones, 392
 - family history and genetic factors, 394
 - ionizing radiation, 394
 - nonoccupational factors, 391, 393
 - reproductive factors, 391–392
 - tobacco smoking, 394
- occupational exposures
 - air pollution, 401
 - cadmium and heavy metals, 400
 - carcinogenic agents, 394–395
 - circadian disruption, 395–396
 - ELF-EMFs, 399–400
 - and environmental agents, 400
 - ethylene oxide, 395–396
 - hormones, antineoplastic drugs/pharmaceuticals, 399
 - IARC monographs, 394–395
 - ionizing radiation, 397–399
 - organic solvents and aromatic hydrocarbons, 399
 - organochlorines, 400
 - pesticides and polychlorinated biphenyls, 400
 - shift work, 396–397
- primary prevention, 565–566

Female reproductive system

- case-control study report, 419
- choriocarcinoma, 419
- epidemiology
 - cases and deaths numbers, 409, 412
 - cervix uteri, 409
 - choriocarcinomas, 410
 - statistics data, 409–410
 - vulvar and vaginal cancers, 410
 - world age-standardized cancer incidence and mortality rates, 409–411
- etiology and lifestyle-related risk factors
 - adenocarcinoma, 413
 - cervical cancer, 411–412
 - endometrial cancer, 412–413
 - fallopian tube cancer, 413
 - ovarian cancer, 413
 - SCCs, 413
- lifestyle habits, 419
- occupational exposures
 - cervical cancer, 414–416
 - endometrial cancer, 416
 - IARC Monographs, 413–414
 - ovarian cancer, 416–419
 - vaginal cancer, 419

Formaldehyde

- chemical carcinogenesis, 35
- in farming, 492
- lung cancer, 3
- lymphohematopoietic malignancies, 516
- nasopharynx cancer, 83
- oral cavity and pharynx, 50
- sinonasal cancer, 148–149

Fungicides, 506–507

G

Gene–environment interactions

- beryllium, 25
- chronic beryllium disease (CBD), 25
- definition, 25
- xenobiotics, 25

Gene–gene interactions, 28

Genetics and heritability

- alleles, 22
- aneuploidy, 21
- autosomal, 21–22
- codominance, 22
- dominant alleles, 22
- double-helical structure, 21
- exons and introns, 22–23
- founder effect, 23
- gene expression, schematic representation, 22
- gene pool, 23
- genetic code, 22
- genetic information, 21
- germ cells, 21
- germline mutations, 23
- isoforms, 22
- messenger RNA (mRNA), 22–23
- polymerase chain reaction (PCR) methodology, 21
- polypeptide, 23
- recessive allele, 22
- single-nucleotide polymorphisms (SNP), 23
- somatic cells, 21
- stop codon, 23
- transcription factors, 23
- variability, 23–24

Genetic susceptibility, 121–122

Genome-wide association studies (GWAS), 28, 322–323, 476–477

Germ cell tumors, 559

Glutathione S-transferases (GSTs)

- and CCBL1, 445
- cigarette smoke, 232
- cumulating evidence, 233
- cytochrome p450 (CYP450), 452
- homozygous deletion, 322
- kidney, 449
- pesticide exposure, 449
- polymorphism, 233

GSTs. *See* Glutathione S-transferases (GSTs)GWAS. *See* Genome-wide association studies (GWAS)**H**

Hairdressers and barbers, bladder cancer

- dry cleaning, 470
- hair dyes, 470
- Scandinavian, lifestyle factors, 468
- smoking effect, 468–469

HALYs. *See* Health-adjusted life years (HALYs)HAS. *See* Hepatic angiosarcoma (HAS)

- HCC. *See* Hepatocellular carcinoma (HCC)
- Head and neck squamous cell carcinomas (HNSCC), 163
- Health-adjusted life years (HALYs), 544
- Hematologic and lymphoid malignancies
- childhood leukemia, 552
 - EMF, 553
 - ionizing radiation, 553
 - metals, 552
 - personal service, 552
 - pesticides, 552
 - solvents
 - benzene, 552
 - Children's Cancer Group, 552–553
 - hydrocarbon, 553
 - IARC, 553
- textiles, 552
- Hepatic angiosarcoma (HAS), 130, 134
- Hepatocellular carcinoma (HCC)
- afatoxin B₁, 132
 - causes, 130–131
 - chronic alcohol intake, 133
 - definition, 129
 - excessive alcohol intake, 131
 - grading, 129
 - HBV, 131–132
 - HCV, 132–133
 - iron absorption and accumulation, 133
 - primary liver cancers, 130
 - staging criteria, 129
 - TP53 genetic alterations, 131
 - well-differentiated tumors, 130
- Herbicides
- carbamate, 505
 - case-control studies, NHL, 499–502
 - glyphosate exposure, 505
 - phenoxy, 504
 - phenoxycetic acids, 499
 - triazine, 504–505
- Hereditary hemochromatosis (HH), 134
- HL. *See* Hodgkin lymphoma (HL)
- HNSCC. *See* Head and neck squamous cell carcinomas (HNSCC)
- Hodgkin lymphoma (HL)
- farm animals, 508
 - follicular lymphoma, 520
 - lymphatic leukemia, 515
 - and NHL, 497
 - organochlorine insecticide exposure, 506
 - triazine herbicides, 505
- HPV. *See* Human papillomavirus (HPV)
- Human papillomavirus (HPV), 152, 161
- I**
- IARC. *See* International Agency for Research on Cancer (IARC)
- ICP-AES. *See* Inductively coupled plasma-atomic emission spectroscopy (ICP-AES)
- IDH1. *See* Isocitrate dehydrogenase (IDH1)
- IGF-1. *See* Insulin-like growth factor 1 (IGF-1)
- Inductively coupled plasma-atomic emission spectroscopy (ICP-AES), 204
- Insulin-like growth factor 1 (IGF-1), 424
- International Agency for Research on Cancer (IARC)
- alcohol, pancreatic cancer, 119
 - beryllium/beryllium compounds, 194
 - bladder cancer risk, 462–464
 - carcinogen, 498
 - carcinogenicity, 465
 - childhood leukaemia, 553
 - chlorophenols, 101
 - classification, 195, 200–201
 - cohort studies, 199
 - diesel exhaust, 195
 - diethylstilbestrol (DES) exposure, 559
 - dioxins, 509
 - dry cleaning, 470
 - Ethylene oxide, 519
 - evaluations, 153, 199
 - exogenous hormones, 392
 - exposure, 152–153, 461–462
 - female breast cancer, 394–396
 - female reproductive systems, 414–415
 - hexavalent chromium, 152
 - human carcinogens, 533–536
 - in humans, 189
 - International Childhood Cancer Cohort Consortium (IC4)
 - formation, 561 - male breast cancer, 402
 - monographs, 394–396
 - occupational carcinogens, 7, 10
 - painters, 468
 - polychlorinated dibenzodioxins and furans, 365
 - SNC, 153
 - soft tissue sarcoma, 346
 - textile industry, 471
 - tobacco smoke, 154, 202
 - TP53 mutation database, 163
 - trichloroethylene, 514
 - wood dust-related SNC, 158–159
- Intestinal-type adenocarcinomas (ITACs), 155, 157, 162–164
- Intestine cancer
- asbestos exposure, 129
 - colon cancer, 128
 - occupational agents, 129
 - rectum cancer, 128
 - small intestine cancer
 - adenocarcinomas, 127
 - age-standardized incidence rates, 127
 - hereditary syndromes, 127
 - malignant lymphomas, 127
 - neuroendocrine tumors, 128
- Ionizing radiation (IR)
- apoptosis, 224
 - and benzene, 498
 - bone marrow, 516
 - cancer mortality, nuclear industry, 517
 - carcinogens, 34
 - and chronic ulceration, 381
 - electromagnetic fields, 402
 - frequency forms, 34
 - HL and CLL, 517
 - leukemias, 516
 - LSS, 516–517
 - medical radiation workers, 517
 - occupational exposure, 399
 - radon, 200
 - reactive oxygen and nitrogen species, 223
 - uranium, 223
 - and UV light, 382
- IR. *See* Ionizing radiation (IR)
- Isocitrate dehydrogenase (IDH1), 482–483
- ITACs. *See* Intestinal-type adenocarcinomas (ITACs)

J

Job exposure matrices (JEMs)
 chromium, 451
 industrial hygiene experts, 453
 occupational gasoline exposure, 451
 and TCE, 440

K

Kidney cancer

agricultural work and exposure
 carcinogenic potential, 449
 chlorinated solvents, 449
 European case-control studies, 449
 GST, 449
 Italian farmers, 445
 metabolism, 449
 occupational health experts, 449
 renal cancer risk, pesticide, herbicide/insecticide exposures,
 445–448
 arsenic exposure, 451
 asbestos, 452–453
 cadmium, 450–451
 chlorinated solvents, 440
 chromium and nickel, 451
 description, 454
 diesel and automotive fumes, 451–452
 fibers and dusts, 453
 lead, 449–450
 occupations and industries, 439–440
 PAHs, 452
 RCC and TCC, 439
 solvents, 440
 trichloroethylene (*see* Trichloroethylene (TCE))
 UV exposures (*see* Ultra violet (UV) exposure)

L

Laryngeal cancer

asbestos
 case-control studies, 173
 cohort studies, 170
 community-based studies, 173
 dose-response analyses, 172
 fibers types, 170, 172
 inhalation studies, 174
 meta-analysis, 171–172
 tobacco smoking, 170–171
 British study, 546
 high-income countries, 169
 HPV infection, 169
 occupational risk factors
 agents, 176
 employment, 176–177
 strong inorganic acid mists, 174–176
 smoking and alcohol, 532
 squamous cell carcinomas, 169
 LDCT. *See* Low-dose CT (LDCT)

Lead

air monitoring measurements and industrial hygiene surveys,
 449–450
 ALAD, 450
 enzymes, heme biosynthetic pathway, 450
 JEMs/occupational experts, 450
 kidney cancer associations, 449
 lead-exposed workers, 449

metal exposures, 450
 National Toxicology Program, 449
 rodents and chronic nephropathy, 449
 smelter workers, Italy, 450
 stomach and lung, 449
 tubular epithelium, 449

Leather dust, sinonasal cancers, 147–148

Life Span Study (LSS), 516–517

Liver cancer

anatomy, 129
 cholangiocarcinoma, 133–134
 epidemiology, 130
 hepatic angiosarcoma (HAS), 134
 hepatocellular carcinoma, 130–131
 mechanisms, 131
 occupational risk factors, 131
 pathology
 CCA, 130
 HCC (*see* hepatocellular carcinoma (HCC))
 hepatic angiosarcoma, 130
 susceptibility
 genetic polymorphisms, 134
 hepatitis viruses, genetic variations, 134–135
 inherited disorders, 134
 types, 131

Localized malignant mesothelioma, 290

Low-dose CT (LDCT), 577–578

LSS. *See* Life Span Study (LSS)

Lung cancer

asbestos, 211–215
 biomarkers
 metal-induced lung carcinogenesis, 219–223
 oxidative DNA damage, 218–219
 PAH exposure, 218
 carcinogen-metabolizing genes, 231–233
 causes, 188
 clinicians and patients, 578
 CXR, 577
 description, 576
 DNA repair and cell-cycle genes, 233–235
 genetic factors, 235–236
 genome-wide association studies, 235
 histopathology
 adenocarcinoma, 181–182
 clinical symptoms, 185–187
 diagnosis, 187–188
 large cell carcinoma, 184–185
 radiographic imaging, 187
 small cell carcinoma, 182–184
 squamous cell carcinoma, 182
 WHO classification, 181
 ionizing radiation-induced carcinogenesis, 223–224
 LDCT, 577
 molecular markers
 asbestos (*see* Asbestos)
 characterization, 243
 description, 243
 occupational exposures and tobacco smoking, 244–245
 NCCN, 577
 NLST, 577
 occupational exposure
 agents, 188
 arsenic, 189
 asbestos (*see* Asbestos)
 beryllium, 194
 bis(chloromethyl) ether, 195

- cadmium, 194–195
- chloromethyl methyl ether, 195
- chromium, 195–196
- coal dust, 196–197
- diesel emissions, 197
- IARC, 188
- ionizing radiation/radon, 200
- nickel, 197–198
- PAHs, 199–200
- painters, 198–199
- silica (*see* Silica, lung cancer)
- tissue analysis, 203–204
- in United Kingdom and France, 188
- welder's pneumoconiosis, 203
- welding, 202–203
- PAHs, 215–218
- radiation exposure, "low-dose" method, 578
- retrospective assessment, asbestos exposure, 205
- tobacco smoking, 181, 188
- Lymphohematopoietic malignancies
 - animal exposures, 507–508
 - chronic immune stimulation, 498
 - description, 507, 520
 - dioxins and furans, 508–509
 - EMF (*see* Electromagnetic fields (EMF))
 - engine exhaust, 515–516
 - farming and pesticides (*see* Farming and pesticides)
 - firefighters, 520
 - formaldehyde, 516
 - fungicides, 506–507
 - healthcare professions, 519–520
 - herbicides (*see* Herbicides)
 - heterogeneous, 497
 - IARC, 498
 - infrequent exposure, 521
 - insecticides (*see* Organophosphate insecticides)
 - ionizing radiation (*see* Ionizing radiation)
 - leukemia, 497–498
 - MM, 497
 - myeloid cell neoplasms and obesity, 498
 - NHL, 497
 - occupational exposures, 498
 - paint-related occupations and exposures, 518–519
 - PCBs, 509–510
 - phenoxy herbicides and organophosphate insecticides, 498
 - rubber industry, 519
 - semiquantitative/quantitative exposure assessment, 521
 - solvents (*see* Solvents, lymphohematopoietic malignancies)
 - teaching professions, 520
- Lynch syndrome I, 128
- M**
- MAHs. *See* Monocyclic aromatic hydrocarbons (MAHs)
- Male breast cancer
 - epidemiology, 401–402
 - lifestyle-related risk factors, 402
 - occupational exposures
 - case-control study, 402–403
 - cohort study, 402
 - extremely-low-frequency electric and magnetic fields, 402
 - heat, 402
 - polycyclic aromatic hydrocarbons (PAHs), 402
- Male reproductive system
 - description, 423
 - prostate cancer (*see* Prostate cancer)
 - testicular cancer (*see* Testicular cancer)
- Malignant melanoma (MM), skin neoplasms
 - acral lentiginous melanoma, 382
 - nevi, 381
 - NM, 382
 - SSM, 382
 - UV light exposure, 381
- Malignant mesotheliomas (MMs)
 - adverse effects, 275
 - in animals, 300–301
 - asbestos exposure (*see* Asbestos)
 - biopersistence, 305
 - biphasic malignant mesothelioma, 292
 - cellular and molecular changes, 311
 - characteristics, 285
 - chrysotile, 281
 - clinical and hygiene assessments, 280
 - clinical markers, 278
 - computed tomography (CT), 266–269
 - conventional X-ray, 278
 - description, 265
 - desmoplastic malignant mesothelioma, 293–294
 - diagnosis, 270, 294–295
 - DNA methylation, 307
 - engineered carbon nanomaterials, 305–306
 - epidemiology
 - asbestos (*see* Asbestos)
 - occupational exposures, 260
 - primary malignant neoplasms, 253
 - epigenetic changes
 - DNA methylation, 331–334
 - histone modification, 330–331
 - miRNAs, 329–330
 - epithelioid malignant mesothelioma, 286–290
 - exhaled breath biomarkers, 339
 - fiber type and mesothelioma, 276–277
 - gene expression profiling
 - array-based experiments, 333
 - comparison, lung cancer, 331
 - and lung adenocarcinoma, 333, 335
 - predicting tumor diagnosis test, 333–334
 - prognostic classifiers, 333
 - ubiquitin-proteasome pathway, 335–336
 - genetic changes
 - bioinformatics methods, 325–326
 - biomarkers (*see* Biomarkers)
 - cytogenetic analysis, 325
 - karyotype analysis, 325
 - LOH analysis, 325
 - genetic susceptibility
 - candidate gene study, 321–322
 - GWAS, 322–323
 - human molecular status, 312
 - hyperplasia
 - diagnosis, 290
 - EMA, 292
 - histological features, 290–291
 - localized malignant mesothelioma, 290
 - membrane filter method, 279
 - mesothelial cells culture, 300–303
 - mineral analysis, lung digests, 281–282
 - mineralogy, 274–275
 - morphological subtypes, 285–286
 - MRI, 269–270

- Malignant mesotheliomas (MMs) (*cont.*)
- neoplastic transformation
 - apoptosis, 311
 - cell cycle, 310
 - epigenetic alterations, 309–310
 - gene mutations, 307–308
 - genomic alterations, 308–309
 - Hippo pathway, 310
 - signaling pathways, 310–311
 - occupational hygiene monitoring, 279
 - paraneoplastic symptoms, 265–266
 - peritoneal mesotheliomas, 276
 - PET, 270
 - pleural effusion, 266
 - pleural fibrosis and plaques, 313
 - protein/peptide markers, 336–339
 - routine light microscopy, 280
 - sarcomatoid, 292–293
 - serosal injury, 307
 - serosal surfaces, 273
 - staging, 270–271
 - surface chemistry and reactivity, 304–305
 - translocation, 299–300
 - transcriptional analyses, 312
- Malignant pleural mesothelioma (MPM), 270, 307–311
- Malignant tumors
- CNS (*see* Central nervous system (CNS))
 - female reproductive system (*see* Female reproductive system)
- Manganese superoxide dismutase (MnSOD), 134, 233, 236, 322
- MAPK/ERK pathway, 214
- Maternal occupational exposure
- bone tumors, 558
 - electronics and chemical industry, 555
 - EMF, 553, 556
 - ionizing radiation, 553
 - metals, 552
 - motor vehicle, health service and food industries, 556
 - neuroblastoma, 557
 - personal service, 552
 - pesticides, 552, 556
 - solvents, 552–553, 555–556
 - textiles, 552, 555
 - urinary system malignancies, 557–558
- MDF. *See* Medium-density fiberboard (MDF)
- Medium-density fiberboard (MDF), 160
- Metal-induced lung carcinogenesis
- arsenic, 219–220
 - beryllium, 220–221
 - cadmium (Cd), 221
 - chromium, 221–222
 - mechanisms, 219
 - nickel, 222–223
- Microsomal epoxide hydrolase (EPHX1), 232, 322
- MMA. *See* Monomethylarsonic acid (MMA)
- MMs. *See* Malignant mesotheliomas (MMs)
- MnSOD. *See* Manganese superoxide dismutase (MnSOD)
- Molecular markers
- lung cancer
 - asbestos (*see* Asbestos)
 - characterization, 243
 - description, 243
 - occupational exposures and tobacco smoking, 244–245
 - pancreatic cancer, 120
- SNC
- and cellular changes, 164
 - chromosomal abnormalities, 163
 - description, 162
 - EGFR mutations, 163
 - epigenetic changes, 162
 - gene expression, 164
 - HNSCC, 163
 - ITAC cases, 163–164
 - protein expression, 164
 - TP53* and *KRAS* gene mutations, 162–163
- Monocyclic aromatic hydrocarbons (MAHs), 399
- Monomethylarsonic acid (MMA), 220
- MPM. *See* Malignant pleural mesothelioma (MPM)
- MPO. *See* Myeloperoxidase (MPO)
- Multiple myeloma (MM)
- asbestos exposure, 265
 - chronic immune stimulation, 498
 - CXR, 266
 - effusion cytology, 267
 - hairy cell leukemia, 508
 - heterologous elements, 292
 - immunostaining protocol, 288
 - lung adenocarcinoma, 329
 - methylation, 331
 - phenoxy herbicides, 504
 - reactive mesothelial hyperplasia, 290
 - serum/pleural fluid, 338
 - solid epithelioid, 266
 - trichloroethylene, 515
 - UV light exposure, 385
- Myeloperoxidase (MPO), 233, 236
- N**
- N*-acetyltransferases (NATs)
- lung cancer, 233
 - N*-acetyltransferase 2 (NAT2)
 - ABPs, 476
 - metabolic polymorphisms, 476
 - N*-oxidation, 465
 - phase II enzymes, 27
- Nanoropes, 306
- Nasopharynx cancer
- case-control studies, 84–92
 - chlorophenols, 101
 - cohort studies, 93–100
 - cotton dust and textile work, 101
 - formaldehyde, 83
 - industrial heat effect, 101
 - nonoccupational risk factors, 50
 - oral cavity and pharynx cancer, 49–50
 - organic solvents, 102
 - strength of evidence, 102
 - wood dust and wood industry work, 83, 101
- National Comprehensive Cancer Network (NCCN), 577
- National Institute of Occupational Safety and Health (NIOSH)
- industrial cohort, herbicide, 366
 - phenoxy acids/chlorophenols, 365
 - plants manufacturing PCP, 367
- National Lung Screening Trial (NLST), 577–578
- National Toxicology Program, 2
- NATs. *See* *N*-acetyltransferases (NATs)
- NCCN. *See* National Comprehensive Cancer Network (NCCN)
- Nervous system tumors, children
- maternal occupational exposures
 - chemical industry, 555
 - electromagnetic fields, 556
 - electronics industry, 555
 - motor vehicle, health service and food industries, 556
 - pesticides, 556

- solvents, 555–556
- textile/garment industry, 555
- paternal occupational exposures
 - description, 556
 - electromagnetic fields, 556
 - motor-vehicle-related occupations, 556–557
 - paints and pigments, 556
 - pesticides, 557
 - solvents, 556
- Neuroblastoma, 557
- Neuroendocrine tumors, 128
- NHL. *See* Non-Hodgkin lymphoma (NHL)
- Nickel
 - carcinogenic effect, 198, 222
 - and chromium compounds, 148
 - compounds and metals, 153
 - de novo methylation, 42
 - epigenetic mechanisms, 223
 - fossil fuels, 222
 - hydroxide and cadmium oxide, 117
 - hypoxic signaling, 223
 - kidney cancer, 450–451
 - lung cancer, 197–198
 - nucleotide and excision repair pathways, 223
 - soluble and insoluble nickel compounds, 222
- NIOSH. *See* National Institute of Occupational Safety and Health (NIOSH)
- NLST. *See* National Lung Screening Trial (NLST)
- NM. *See* Nodular melanoma (NM)
- NMSC. *See* Non-melanoma skin cancer (NMSC)
- Nodular melanoma (NM), 382
- Non-Hodgkin lymphoma (NHL)
 - alcohol consumption, 498
 - benzene and trichloroethylene exposure, 514
 - glyphosate exposure, 505
 - phenoxy herbicides, 499
 - rubber industry, 519
 - terbufos with leukemia, 505
- Non-intestinal type of adenocarcinomas (non-ITACs), 155–157, 162
- Nonionizing radiation
 - chemical agents, 488
 - electrical occupations, 488
 - extremely low-frequency (ELF) and brain cancer, 487–488
 - magnetic field exposure, 488
 - parental occupational exposures, 488
 - radiofrequency (RF) radiation, 488–489
 - transportation workers and welders, 488
 - ultraviolet (UV) radiation, 489
- non-ITACs. *See* Non-intestinal type of adenocarcinomas (non-ITACs)
- Non-melanoma skin cancer (NMSC)
 - cancer site, 538
 - farming, 540
 - and MM, 381
 - solar radiation and mineral oils, 547
- Nonoccupational risk factors
 - nasopharynx cancer, 50
 - oral cavity and pharynx cancer, 50
 - prostate cancer, 423–424
 - soft tissue sarcoma (STS), 345–346
 - testicular cancer, 428–429
- O**
- Occupational cancer research
 - acrylonitrile and lung cancer, 3
 - animal experimentation
 - disagreements, 5
 - exposure route, 4
 - genetic and cellular characteristics, 4
 - phylogenetic scale, 4
 - asbestos, 11–12
 - 1,3-butadiene, 12–13
 - cadmium and cadmium compounds, 12
 - carcinogens, 5
 - chemicals risk to humans, 4
 - coal tar, active ingredients, 1
 - definite and probable occupational risk factors, 7–9
 - diesel and gasoline engine emissions, 11
 - environmentalism, 2
 - epidemiology, 4
 - IARC monographs
 - carcinogenicity evidence, 5–6
 - carcinogens rating, 10
 - classes, 6
 - classifications and guidelines, 7
 - evaluations, 5
 - human carcinogenicity, 6
 - limitations, 6–7
 - objective, 5
 - knowledge evolution, 7–10
 - leukemia risk, 3
 - lists interpretation, 10
 - man-made mineral fibers (MMMF), 2
 - methodological considerations
 - community-based case-control studies, 14–15
 - continued importance, research, 15–16
 - epidemiologic research, 15
 - industry-based studies, 14
 - National Toxicology Program, 2
 - polycyclic aromatic hydrocarbons (PAHs),
 - 1, 10–11
 - radium and radon, 13
 - respiratory cancer risks, 2
 - risk factors, 2–3
 - scrotal cancer, 1
 - short-term tests and structure-activity relationships, 5
 - soot wart, 1
 - styrene, 12
 - vinyl chloride (VC), 13
- Occupational risk factors
 - biliary tract cancer, 135
 - cancer, definite and probable, 7–8
 - liver cancer, 131
 - oral cavity and pharynx cancer (*see* Oral cavity and pharynx cancer)
 - pancreatic cancer, 107
- SNC
 - adenocarcinomas, 141
 - case-control studies, 141, 144–145
 - EBV, 152
 - formaldehyde, 148–149
 - histological subtypes, 152
 - histological types, 140
 - HPV, 152
 - human carcinogens, 140
 - leather dust, 147–148
 - nickel and chromium compounds, 148
 - paranasal sinuses and mastoid process, 150–151
 - pooled dataset, 141
 - squamous cell carcinoma, 151
 - textile workers/textile dust, 149–150
 - tobacco-associated cancers, 152
 - wood dust (*see* Wood dust, SNC)

- Oral cavity and pharynx cancer
 - case-control studies, 51–66
 - cohort studies, 67–80
 - cotton dust and textile work, 82
 - diesel engine exhaust and vehicle repair mechanics, 82
 - Finnish cohort population, 81
 - formaldehyde, 50
 - leather dust and leather industry work, 81
 - man-made mineral fiber (MMMF) factory, 82–83
 - meat industry, exposures, 82
 - nasopharynx cancer, 49–50
 - nonoccupational risk factors, 50
 - Scandinavian cohort of employees, 82–83
 - strength of evidence, 102
 - welding fumes and welding as an occupation, 82
 - wood dust and wood industry work, 81–82
- Organophosphate insecticides
 - chlordane and dieldrin, 506
 - chlorpyrifos, 505
 - lindane and leukemia, 506
 - malathion and diazinon, 505–506
 - pyrethrin, 506
- Ovarian cancer
 - etiology and lifestyle-related risk factors, 413
 - incidence and mortality rates, 409
 - occupational exposures
 - aromatic hydrocarbons and exhaust fumes, 418
 - asbestos, 416–417
 - clerical and professional occupations, 418
 - cohort study, 418
 - hormones and antineoplastic drugs, 418
 - IARC Working Group report, 418
 - ionizing radiation, 417
 - organic solvents, 418
- P**
 - PAFs. *See* Population attributable fractions (PAFs)
 - PAHs. *See* Polycyclic aromatic hydrocarbons (PAHs)
 - Pancreatic cancer
 - carcinogenic mechanisms, 120–121
 - clinical and pathological features
 - biliary obstruction, 120
 - molecular markers, 120
 - pain, 120
 - symptoms, 120
 - vascular and perineural invasion, 120
 - definition, 107
 - genetic susceptibility, 121–122
 - non-occupational risk factors
 - alcohol consumption, 119
 - coffee consumption, 119
 - diabetes, 119–120
 - nutrition, 119
 - obesity, 119
 - pancreatitis, 120
 - smoking, 119
 - occupational risk factors
 - case-control studies, 114–116
 - chemical, petroleum and related processing industries, 107, 113, 116–117
 - cohort studies, 108–113
 - disease, aggressive nature, 118
 - healthy worker effect, 118
 - leather industries, 118
 - metal manufacturing industries, 117
 - occupation/industry titles, 118
 - printing and paper manufacturing industries, 117
 - solvent-related occupations, 118
 - textile industries, 118
 - transport and communication industries, 117–118
- Paternal occupational exposures
 - bone tumors, 558
 - breastfeeding, 551
 - carcinogen, 551
 - childhood leukemia, 559–560
 - description, 551, 553
 - electromagnetic fields, 556
 - ELF-MFs, 554–555
 - International Childhood Cancer Cohort Consortium (IC4), 561
 - ionizing radiation, 554
 - limitations, 560
 - motor-vehicle-related occupations, 554, 556–557
 - nervous system tumors, 560
 - neuroblastoma, 557
 - paints and pigments, 554, 556
 - pesticides, 555, 557
 - solvents, 553–554, 556
 - take-home exposure, 551
 - urinary system malignancies, 558
 - US National Children's Study (NCS), 560
 - woodwork, 554
- PCBs. *See* Polychlorinated biphenyls (PCBs)
- Personal identification numbers (PIDs), 587
- PET. *See* Positron-emission tomography (PET)
- Phenotype vs. genotype
 - BRCA2 mutation, 24
 - genetic code, 24
 - high-penetrance alleles, 24
 - low-penetrance alleles, 24–25
 - moderate-penetrance alleles, 24
- PIDs. *See* Personal identification numbers (PIDs)
- Pleural mesothelial cells
 - chromosomal abnormalities, 309
 - gene mutations, 307
 - genomic alterations, 301–303
- Polychlorinated biphenyls (PCBs)
 - blood/adipose tissue, 509–510
 - breast cancer, 400
 - coolants and lubricants, 509
 - and dioxins, 36
 - hexachlorobenzene (HCB), 579
 - prostate cancer, 428
 - testicular cancer, 429
- Polycyclic aromatic hydrocarbons (PAHs), 10–11, 199–200
 - aluminum production, 465
 - asphalt workers, printers, machinists and mechanics, 452
 - benzene, 467, 470
 - benzo[a]pyrene, 199, 452
 - b-naphthylamine, 473
 - cocarcinogenesis mechanism, 217–218
 - fossil fuels, organic material, 452
 - gene-environment interaction, 452
 - GSTs and cytochrome p450 (CYP450), 452
 - hydrogen peroxide, CYP2S1, 217
 - involuntary tobacco smoking, 216
 - lung carcinogens, 216
 - metabolic activation, procarcinogens, 216–217
 - nitrosamine, 220
 - tobacco smoke, 216
- Polymorphisms and cancer
 - phase I
 - CYP1A1, 26
 - CYP1B1, 26

- CYP2E1*, 26
- cytochrome P450 enzyme (CYP) superfamily, 26
- organophosphate pesticides, 26
- phase II
 - glutathione S-transferases (GST), 27
 - N*-acetyltransferases (NAT), 27
 - NAD(P)H:quinone oxidoreductase (NQO1), 27
- phenotypic variability, 27
- specific genetic variants, 27
- susceptibility genes, 27
- Population attributable fractions (PAFs), 568
- Population stratification
 - allele frequencies, 27
 - nonhomogeneous genetic makeup, 28
 - race/ethnicity, 28
 - schematic diagram, 28
- Positron-emission tomography (PET), 187
- Primary prevention, occupational cancer
 - asbestos, lung cancer and mesothelioma, 567
 - benzene and leukemia, 567–568
 - bladder cancer and aromatic amines, 566
 - breast cancer, nuns, 566
 - circadian rhythm and female breast cancer, 565–566
 - description, 565
 - infrastructural factors, development, 570–571
 - risk
 - identification, 568
 - quantification (*see* Risk)
 - reduction/elimination, 569
 - scrotal cancer, chimney sweeps, 566
 - sinonasal cancer and wood dust, 566
 - skin cancer, breast cancer and mesothelioma, 565
 - TLV, 570
 - tobacco smoking, 565
 - VC and angiosarcoma, 567
- Prostate cancer
 - epidemiology, 423
 - nonoccupational risk factors
 - childhood environment, 424
 - effect, diabetes, 424
 - familial clustering, 423
 - genome-wide association studies, 423–424
 - heterogeneous, 424
 - IGF-1, 424
 - incidence and mortality, 424
 - lycopene and selenium, 424
 - metabolic syndrome, 424
 - risk factors, 423–424
 - smoking, 424
 - occupational risk factors
 - cadmium, 425
 - carcinogens, 424
 - farming and pesticides (*see* Farming and pesticides)
 - meta-analysis, 425
 - metal working and rubber industry, 425
 - pesticides, 424
 - SIR, 424
- R**
- Radical oxygen species (ROS), 158, 160
- Radiofrequency (RF) radiation, 488–489
- Radium and radon, 13
- RCC. *See* Renal cell carcinoma (RCC)
- RCS. *See* Respirable crystalline silica (RCS)
- Rectum cancer, 128
- Renal cell carcinoma (RCC)
 - cadmium exposure, 451
 - chlorinated solvents, 440
 - European case-control study, 453
 - gasoline fumes, 451
 - and GST, 445
 - herbicides, 449
 - homozygous wild-type and heterozygous alleles, 449
 - oncocyoma and chromophobe tumors, 439
 - parenchyma, 439
 - and TCE, 440
 - xenobiotic metabolism, 454
- REP. *See* Risk exposure period (REP)
- Respirable crystalline silica (RCS), 541
- Risk
 - identification, 568
 - quantification
 - asbestos, 569
 - carcinogens, 569
 - CAREX, 569
 - drawback, 569
 - FINJEM, 569
 - PAFs, 568
 - tobacco smoking habits, 569
- Risk exposure period (REP)
 - deaths and cancer registrations, 537
 - hematopoietic neoplasms, 536
- ROS. *See* Radical oxygen species (ROS)
- S**
- SAED. *See* Selected area electron diffraction (SAED)
- Sarcomatoid malignant mesothelioma
 - and biphasic, 286
 - desmoplastic features, 293
 - diagnosis, 292, 294–295
 - epithelioid, 286
 - leiomyoid features, 292
- SBR. *See* Styrene-butadiene rubber (SBR)
- Scanning electron microscopy (SEM), 194, 204
- SCCs. *See* Squamous cell carcinomas (SCCs)
- Screening, occupational cancer
 - biomarkers and biomonitoring, 574
 - bladder cancer, 578
 - burden of disease, 574
 - communication, 576
 - cytogenetic techniques, 579
 - definitions, 573–574
 - factors, 575
 - health effects, 579
 - health outcome, 574–575
 - hematologic cancers, 579
 - and latency, 575
 - lung cancer (*see* Lung cancer)
 - malignancy occurs, cluster, 576
 - medical benefits and concerns, 575
 - multiple agents, 579
 - pleural mesothelioma, 579
 - quality assurance and control, 576
 - sentinel events, 576
 - serum biomarkers, 579
 - skin cancer, 578–579
 - sound occupational health practice, 575
 - test availability, 575
 - testing modalities, 576
 - World Trade Center (WTC), 579

- Secondary ion mass spectrometry (SIMS), 204
 Secondhand tobacco smoke (SHTS), 202
 SEER. *See* Surveillance Epidemiology and End Results (SEER)
 Selected area electron diffraction (SAED), 204
 SEM. *See* Scanning electron microscopy (SEM)
 SHTS. *See* Secondhand tobacco smoke (SHTS)
 Sidestream smoke (SSS), 202
 Silica, lung cancer
 ATS, 201
 coal mining/coal dust imparts, 201
 cristobalite/tridymite, 201
 exposure-response trends, 201
 histomorphology, 202
 IARC, 201
 occupations with crystalline, 200
 secondhand tobacco smoke, 202
 silicosis, 201–202
 SIMS. *See* Secondary ion mass spectrometry (SIMS)
 Sinonasal cancer (SNC)
 carcinogenesis (*see* Carcinogenesis)
 description, 140
 epidemiology and occupational risk factors (*see* Occupational risk factors)
 ethmoid labyrinth, adult, 140
 exposure characteristics
 chromium VI, 152–153
 formaldehyde, 152
 IARC, 152
 nickel compounds and metal, 153
 shoe and leather work, 154
 substances, 152
 tobacco smoking, 154
 wood dust, 152
 molecular markers
 and cellular changes, 164
 chromosomal abnormalities, 163
 description, 162
 EGFR mutations, 163
 epigenetic changes, 162
 gene expression, 164
 HNSCC, 163
 ITAC cases, 163–164
 protein expression, 164
 TP53 and *KRAS* gene mutations, 162–163
 nasal cavities and paranasal sinuses, 139–140
 nasal vestibule, 139
 nose and paranasal cavities, 139
 pathology
 adenocarcinomas, 154–155
 histological types, 154–155
 intestinal-type adenocarcinoma, 155
 ITACs, 157
 malignancies, 154
 malignant epithelial tumors, 154
 maxillary and ethmoid carcinomas, 154
 non-intestinal-type adenocarcinoma, 155–157
 squamous cell carcinoma, 155
 WHO classification of tumours, 154
 SIR. *See* Standardized incidence ratio (SIR)
 Skin cancer
 chemical and physical workplace exposures, 388
 description, 379
 epidemiology and surveillance, 386–387
 intervention research, 387–388
 melanoma and nonmelanoma, 578–579
 occupational exposure factors
 arsenic, 384
 investigating associations studies, 382–384
 ionizing radiation, 386
 metalworking fluids, 384–385
 organic compounds, 382, 384
 polycyclic aromatic hydrocarbons (PAHs), 382, 384
 shift work, 386
 UV light, 382, 385
 workplace chemicals, 385
 occupational workplace risk factors
 AK, 380–381
 BCC, 380
 MM pathogenesis, 381–382
 SCCs, 381
 prevention measurement, 387
 ultraviolet radiation, 578–579
 SNC. *See* Sinonasal cancer (SNC)
 Soft tissue sarcoma (STS)
 clinical and pathological features, 370–371
 epidemiology and nonoccupational risk factors, 345–346
 exposure assessment, 370, 372
 exposure to agents, 366–368
 ionizing radiation, 370
 mortality/incidence, 367–368
 NIOSH/IARC, 365–367
 nonoccupational exposure, 367
 occupational risk factors
 case-control studies, 346, 358–364
 cohort studies, 346–357
 high-dose ionizing radiation, 346
 phenoxy herbicides, 345–346
 polychlorinated dibenzodioxins and furans, 346, 365
 standardized incidence ratio (SIR), 365
 TCDD, 346
 phenoxy acids or chlorophenols, 366–369
 population-based case control studies, 365–366, 369
 Swedish pesticide applicators, 369
 TCDD, 372–373
 time-and space-clustering study, 369
 vinyl chloride, 369–370
 Solvents, lymphohematopoietic malignancies
 benzene
 AML, 510
 lymphoid neoplasms, 511–514
 petroleum refineries and petrochemical plants, 510
 styrene, 514
 toluene and xylene, 514
 chlorinated solvents, 514–515
 description, 510
 gene-environment interaction, 515
 Squamous cell carcinomas (SCCs)
 chromium compounds/alloys, 102
 epithelial tumors, nasal cavity and paranasal sinuses, 154
 female reproductive system, 102
 formaldehyde, 83
 laryngeal cancer, 169
 lung cancer, 182
 occupational exposure, 154
 sinonasal cancer, 141, 146, 155
 skin neoplasms, 381
 SSM. *See* Superficial spreading melanoma (SSM)
 SSS. *See* Sidestream smoke (SSS)
 Standardized incidence ratio (SIR), 471–472
 STS. *See* Soft tissue sarcoma (STS)
 Styrene, 12–13, 405, 514
 Styrene-butadiene rubber (SBR), 12–13

Superficial spreading melanoma (SSM), 382
Superior vena cava (SVC), 185
Surveillance Epidemiology and End Results (SEER), 483–484
SVC. *See* Superior vena cava (SVC)

T

TCC. *See* Transitional cell carcinoma (TCC)
TCDD. *See* 2,4,5,7-tetrachlorodibenzo-p-dioxin (TCDD)
TCE. *See* Trichloroethylene (TCE)
TDS. *See* Testicular dysgenesis syndrome (TDS)
TEM. *See* Transmission electron microscopy (TEM)
Testicular cancer
 epidemiology, 428
 firefighting, 432
 nonoccupational risk factors
 antiestrogenic and antiandrogenic effects, 429
 carcinoma, 428
 cryptorchidism, 428
 description, 428–429
 endocrine-disrupting chemicals, 429
 exogenous estrogens, 429
 genome-wide association studies, 429
 spermatogonia, 429
 TDS, 429
 occupational risk factors
 categories, socioeconomic status occupations, 429
 farming and pesticides, 430–432
 hospital-based case-control study, 429
 pesticides and firefighter, 429
 Royal Air Force, 429–430
 susceptibility, 429
Testicular dysgenesis syndrome (TDS), 429
2,4,5,7-Tetrachlorodibenzo-p-dioxin (TCDD)
 cohort studies, 346–357
 lymphohematopoietic cancers, 509
 phenoxy herbicides, 366
 serum concentrations, 372
Threshold limit values (TLV), 570
Transitional cell carcinoma (TCC), 439
Transmission electron microscopy (TEM), 194, 204
Trichloroethylene (TCE)
 carcinogenic to humans, 440
 GST, 445
 high-quality exposure assessment and robustness, 445
 human health risk assessment, 445
 kidney cancer risk and occupational studies,
 440–444
 meta-analyses, 440, 445
 nephrotoxicity, 440
 occupational exposure and RCC risk, 440
 polymorphisms, genes, 445
 renal adenoma and adenocarcinoma, 440
 US EPA, 440

U

Ultra violet (UV) exposure
 European case-control study, 453
 kidney cancer mortality and incidence, 453
 occupational/industry studies, 453

 serum vitamin D level, 453
 solar UV rays, 453
 vitamin D metabolism, 453
UV exposure. *See* Ultra violet (UV) exposure

V

VATS. *See* Video-assisted thoracoscopic surgery (VATS)
VC. *See* Vinyl chloride (VC)
Video-assisted thoracoscopic surgery (VATS), 187
Vinyl chloride (VC), 13, 567
Vulvar and vaginal cancers, 410, 413

W

WEL. *See* Workplace exposure limit (WEL)
Wood dust, SNC
 carcinogenesis
 animal carcinogenicity studies, 160
 cellular toxicity/mutagenicity, 158
 characteristic, 159
 chemical composition, 157
 DNA damage, 160
 exert human toxicity, 160
 genetic and alterations in human, 161
 genotoxicity, 161
 inflammatory response, 160–161
 molecular mechanisms, 157–159
 nonpolar organic extractives, 157
 particle-induced toxicity, 160
 quercetin, 159
 substances with biological activity, 157
 occupational risk factors
 adenocarcinoma, 141
 case-control studies, pooled analyses, 141–144
 cohort studies, 146
 epidemiological studies, 141
 squamous cell carcinoma, 141, 146
Workplace exposure limit (WEL), 541

X

Xenobiotic metabolism and excretion
 activation step, 25–26
 aryl hydrocarbon receptor (AHR), 26
 conjugation, 25–26
 direct carcinogens, 25
 enzymes, 26
 procarcinogens, 25
Xeroderma pigmentosum complementary group C (XPC), 121, 234
XPA protein, 37, 121, 234
XPC. *See* Xeroderma pigmentosum complementary group C (XPC)
X-ray repair cross-complementing group 1 (XRCC1)
 Arg399Gln, 27
 ionizing radiation and alkylating agents, 235
 meta-analysis, 235
XRCC1. *See* X-ray repair cross-complementing group 1 (XRCC1)

Y

Years of life lived with a disability (YLDs), 544–546